Pembrolizumab/Axitinib Combo Approved in Europe for Frontline RCC

Sep 4, 2019 – The European Commission has approved the combination of pembrolizumab and axitinib for the frontline treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on findings from the phase III KEYNOTE-426 trial, in which the combination led to a 47% reduction in the risk of death compared with sunitinib in this patient population (HR, 0.53; 95% CI, 0.38-0.74; P = .0005).2 The pembrolizumab/axitinib combination … (leggi tutto)